

REFERENCES

A

- Abess, A.; Keel, D.M. and Graham, B.S. (2003):**
Flagellate hyper-pigmentation following intralesional bleomycin treatment of verruca plantaris. Arch. Dermatol., 139: 337-339.
- Agius, E.; Mooney, J.M.; Bezzina, A.C. and Yu, R.C. (2006):**
Dermojet delivery of bleomycin for the treatment of recalcitrant plantar warts. J. Dermatol. Treat., 17: 112-116.
- Aksakal, A.B.; Ozden, M.G.; Atahan, C. and Onder, M. (2008):**
Successful treatment of verruca plantaris with a single sublesional injection of interferon- α 2a. Clin. Exp. Dermatol., 34: 14-19.
- Alberts, D.S.; Hess, L.M.; Von Hoff, D.D. and Dorr, R.T. (2009):**
Pharmacology and therapeutics in gynecologic cancer. In: Principles and practice of gynecologic oncology, edited by Barakat, R.R.; Pertelman, R.O.; Markman, M. and Randall, M., 5th edition, Williams and Wilkins scientific publications, Lippincott, pp. 413-429.
- Allen, A.L. and Fosko, S.W. (1998):**
Lymphangitis as a complication of intralesional bleomycin therapy. J. Am. Acad. Dermatol., 120: 963-964.
- Amer, M.; Diab, N.; Ramadan, A.; Galal, A. and Salem, A. (1988):**
Therapeutic evaluation for intralesional injection of bleomycin sulfate in 143 resistant warts. J. Am. Acad. Dermatol., 18: 1313-1316.
- Androphy, E.J. and Lowy, D.R. (2008):**
Warts. In: Fitzpatrick's Dermatology in general medicine, edited by Wolff, K. ; Coldsmith, L.A. ; Katz, S.I. ; Gilchrest, B.A. ; Paller, A.S. and Leffell, D.J., McGraw-Hill scientific publications, United states of America, pp. 1914.

Arndt, K.A.; Bowers, K.E. and Chauttani, A.R. (1995):

Warts. In: manual of dermatologic therapeutics with essential diagnosis, edited by Arndt, K.A.; Bowers, K.E. and Chauttani, A.R., 5th edition, Little and Brown scientific publications, New York, pp. 207-215.

Askew, D.A.; Mickan, S.M.; Soyer, H.P. and Wilkinson, D. (2009):

Effectiveness of 5-fluorouracil treatment for actinic keratosis- a systematic review of randomized controlled trials. *Int. J. Dermatol.*, 48: 453-463.

Atzori, L.; Pinna, A.L. and Ferreli, C. (2003):

Extensive and recalcitrant verrucae vulgaris of the great toe treated with imiquimod 5% cream. *J. Eur. Acad. Dermatol. Venereol.*, 17: 348-372.

Avilés, A.; Díaz-Maqueo, J.C.; Talavera, A.; Guzmán, R. and García, E.L. (1991):

Growth and development of children of mothers treated with chemotherapy during pregnancy: current status of 43 children. *Am. J. Hematol.*, 36: 243-248.

B

Bacelieri, R. and Johnson, S. (2005):

Cutaneous warts: an evidence-based approach to therapy. *Am. Fam. Physician.* 72: 647-652.

Bae, J.M.; Kang, H.; Kim, H.O. and Park, Y.M. (2009):

Differential diagnosis of plantar wart from corn, callus and healed wart with the aid of dermoscopy. *Br. J. Dermatol.*, 160: 220-222.

Bakker, P.J. (1982):

Intralesional treatment of warts with bleomycin. *Br. J. Dermatol.*, 107: 611-615.

Baran, R. (2003):

Periungual tissue disorders. In: A text atlas of nail disorders techniques in investigation and diagnosis, edited by Baran, R.; Dawber, P.R.; Haneke, E.; Tosti, A. and Bristow, I., 3rd edition, Martin and Duntiz scientific publications, London, pp. 126-131.

Beglin, M. (2009):

Strategies of high and low-risk human papillomavirus for immune evasion and episomal Maintenance. Thesis, Northwestern university, pp.10-13.

Berth-Jones, J. (2004):

Topical therapy. In: Rook's textbook of dermatology, edited by Burns, T.; Breathnach, S.; Cox, N. and Griffiths, C., 7th edition, Blackwell scientific publications, Oxford, London, pp. 3989-3990.

Bharti, A.C.; Shukla, S.; Mahata, S.; Hedau, S. and Das, B.C. (2009):

Anti-human papillomavirus therapeutics: facts & future. Indian J. Med. Res., 130: 296-310.

Blugerman, G.; Schavelzon, D. and Dreszman, R.(2003):

Intralesional use of 5-FU in subcutaneous fibrosis. J. Drugs Dermatol., 2: 169-71.

Bouwes Bavinck, J.N.; Euvrard, S.; Naldi, L.; Nindl, I.; Proby, C.M.; Neale, R. et al., (2007):

Keratotic skin lesions and other risk factors are associated with skin cancer in organ-transplant recipients: a case-control study in The Netherlands, United Kingdom, Germany, France, and Italy. J. Invest. Dermatol., 127: 1647-1656.

Bran, R. and Richert, B. (2006):

Common nail tumors. Dermatol. Clin., 24: 297-311.

Brederode, R.L. and Engel, E.D. (2001):

Combined cryotherapy/70% salicylic acid treatment for plantar verrucae. J. Foot Ankle Surg., 40: 36-41.

Bremner, R.M. (1976):

Warts: treatment with intralesional bleomycin. Cutis., 18: 264-266.

Bunney, M.H. (1973):

The treatment of plantar warts with 5-fluorouracil. Br. J. Dermatol., 89: 96-97.

Bunney, M.H.; Nolan, M.W.; Buxton, P.K.; Going, S.M. and Prescott, R.J. (1984):

The treatment of resistant warts with intralesional bleomycin: a controlled clinical trial. Br. J. Dermatol., 111: 197-207.

Byrne, C.M.; Thompson, J.F.; Johnston, H.; Hersey, P.; Quinn, M.J.; Hughes, T.M. et al., (2005):

Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Res., 15: 45-51.

C

Cheng, Y.W.; Wu, M.F.; Wang, J.; Yeh, K.T.; Goan, Y.G.; Chiou, H.L. et al., (2007):

Human papillomavirus 16/18 E6 oncoprotein is expressed in lung cancer and related with p53 inactivation. Cancer Res., 67: 10686-10693.

Chern, E. and Cheng, Y.W. (2009):

Treatment of recalcitrant periungual warts with cimetidine in pediatrics. J. Dermatol. Treat., 1: 1-3.

Clark-Loeser, L.C.; Washenik, K. and Shupack, J.L. (2003):

Topical cytotoxic agents. In: Fitzpatrick's dermatology in general medicine, edited by Freedberg, I.M.; Eisen, A.Z.; Wolff, K.; Austen, K.; Goldsmith, L.A. and Katz, S.I., 6th edition, McGraw-Hill scientific publications, New York, pp. 2355-2356.

Conley, L. and Buka, R.L. (2005):

Painful pedal lesions. Cortlandt Forum., 17: 56-61.

Cordero, A.A.; Guglielmi, H.A. and Woscoff, A. (1980):

The common wart: intralesional treatment with bleomycin sulfate. Cutis, 26: 319-320.

D

Dammak, A.; Camus, M.; Anyfantakis, V. and Guillet, G. (2009):
Successful treatment of Hailey-Hailey disease with topical 5-fluorouracil. *Br. J. Dermatol.*, 161: 967-968.

Darougheh, A.; Asilian. A. and Shariatic F. (2007):
Intralesional triamcinolone alone or in combination with 5-fluorouracil for the treatment of keloid and hypertrophic scars. *Clin. Exper. Dermatol.*, 34: 219-223.

Dawber, R.; Bristow, I. and Turner, W. (2005):
Nail disorders. In: *Text atlas of pediatric Dermatology*, edited by Dawber, R.; Bristow, I. and Turner, W., 2nd edition, Taylor and Frances scientific publications, London, pp.71.

De Berker, D.A.; Baran, R. and Dawber, R.P. (2004):
Disorders of nails. In: *Rook's textbook of dermatology*, edited by Burns, T.; Breathnach, S.; Cox, N. and Griffiths, C., 7th edition, Blackwell scientific publications, Oxford, pp. 3172.

De Jong, A.; van der Burg, S.H.; Kwappenberg, K.M.; van der Hulst, J.M.; Franken, K.L.; Geluk, A. et al., (2002):
Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. *Cancer Res.*, 62: 472-479.

Dhar, S.B.; Rashid, M.M.; Islam, A.Z. and Bhuiyan, M. S. (2009):
Intralesional bleomycin in the treatment of cutaneous warts: A randomized clinical trial comparing it with cryotherapy. *Indian J. Dermatol. Venereol. Leprol.*, 75: 262-266.

Dillner, J.; Arbyn, M. and Dillner, L. (2007):
Translational mini-review series on vaccines: Monitoring of human papillomavirus vaccination. *Clin. Exp. Immunol.*, 148: 199-207.

Dogra, A.; Gupta, S.K. and Bansal, A. (2006):
Comparative efficacy of topical 5% 5-fluorouracil with electrosurgery in treatment of warts. *Indian J. Dermatol.*, 51: 108-110.

Doorbar, J. (2005):

The papillomavirus life cycle. J. Clin. Virol., 32: 57.

E

Ebrahimi, S.; Dabiri, N.; Jamshidnejad, E. and Sarkari, B. (2007):

Efficacy of 10% silver nitrate solution in the treatment of common warts: a placebo-controlled, randomized, clinical trial. Int. J. Dermatol., 46: 215-217.

Elder, D.E.; Elenitsas, R.; Johnson, B.L.; Ioffreda, M.D. and Miller, O.F. (2007):

Plantar warts. In: Atlas and synopsis of lever's histopathology of the skin, edited by Elder, D.E.; Elenitsas, R.; Johnson, B.L.; Ioffreda, M.D. and Miller, O.F., 2nd edition, Williams and Wilkins scientific publications, Lippincott, pp. 53.

F

Figueroa, S. and Gennaro, A.R. (1980):

Intralesional bleomycin injection in treatment of condyloma acuminatum. Dis. Colon Rectum, 23: 550-551.

Forbes, M.A. and Schmid, M.M. (2006):

Use of OTC essential oils to clear plantar warts. Nurse. Pract., 31: 53-57

Fox, P.A. and Tung, M.Y. (2005):

Human papillomavirus: burden of illness and treatment cost considerations. Am. J. Clin. Dermatol., 6: 365-381.

Fromer, M. J. (2005):

Hodgkin lymphoma: chemo regimens need not include bleomycin. J. Clinic. Oncolog., 23: 7614-7620.

G

- Gamil, H.; Elgharib, I.; Nofal, A. and Abd-Elaziz, T. (2009):**
Intralesional immunotherapy of plantar warts report of a new antigen combination. J. Am. Acad. Dermatol., 63: 40-43.
- Gammon, D.C.; Reed, K.A.; Patel, M. and Balaji K.C. (2008):**
Intraurethral fluorouracil and lidocaine for intraurethral condyloma acuminata. Am. J. Health Syst. Pharm., 65: 1830-1833.
- Ganguly, N. and Parihar, S.P. (2009):**
Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis. J. Biosci., 34: 113-123.
- Gearheart, P.A.; Randall, T.C. and Buckley, R.M. (2009):**
Human papillomavirus, accessed 10 september 2010, <<http://eMedicine Infectious disease.htm>>.
- Gibbs, S.; Harvey, I.; Sterling, J. And Sterk, R. (2002):**
Local treatment for cutaneous warts: systemic review. BMJ., 325 : 461-467
- Gillson, M.L. (2009):**
Human papillomavirus and prevention and therapy of head and neck cancer. In: Head and neck cancer: A multidisciplinary approach, edited by Harrison, L.B. ; Sessions, R.B. and Hong, W.K., 3rd edition, Williams and Wilkins scientific publications, Lippincott, pp. 906-913.
- Glass, A.T. and Solomon, B.A. (1996):**
Cimitidine therapy for recalcitrant warts in adults. Arch. Dermatol., 132: 680-682.
- Gonzalez, F.U.; Martinez, A.A.; Rodriquez, P.G. and Garcia-Perez, A. (1986):**
Cutaneous toxicity of intralesional bleomycin administration in the treatment of periungual warts. Arch. Dermatol., 122: 974-975.

Good, L. M.; Miller, M. D. and High, W.A. (2010):

Intralesional agents have a role in the management of cutaneous malignancies: a review. J. Am. Acad. Dermatol., 11: 1-10.

Goodheart, H.P.(2007):

Dermatology rounds: Treatment of nongenital warts. J. Women's Health Primary Care, 4: 11-16.

Gothelf, A.; Mir, L.M. and Gehl, J. (2003):

Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat. Rev., 29: 371-387.

Grem, J.L. (2006):

5-Fluoropyrimidines. In: Cancer chemotherapy & biotherapy principles & practice, edited by Chabner, B.A. and Longo, D.L., 4th edition, Williams and Wilkins scientific publications, Lippincott, pp.126-144.

Gross, K.; Kircik, L. and Kricorian, G. (2007):

Five-fluorouracil 5% cream for treatment of small superficial Basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction. Dermatol. Surg., 33: 433-439.

H

Hayes, M.E. and O'Keefe, E.J. (1986):

Reduced dose of bleomycin in the treatment of recalcitrant warts. J. Am. Acad. Dermatol., 15: 1002-1006.

Hebner, C.M. and Laimins, L.A. (2006):

Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity. Rev. Med. Virol., 16: 83-97.

Hecht, S.M. (2000):

Bleomycin: new perspectives on the mechanism of action. J. Nat. Prod., 63: 158-168.

Heller, R.; Jaroszeski, M.J.; Reintgen, D.S.; Puleo, C.A.; De Conti, R.C.; Gilbert, R.A., et al., (1998):

Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. *Cancer*, 83: 148-157.

High, W.A.; Tyring, S.K. and Taylor, R.S. (2003):

Rapidly enlarging growth of the proximal nail fold. *Dermatol. Surg.*, 29: 984-986.

Holmes, C.E.; Abraham, A.T.; Hecht, S.M.; Florentz, C. and Giegé, R. (1996):

Fe bleomycin as a probe of RNA conformation. *Nucleic Acids Res.*, 27: 3399-3406.

Hoory, T.; Monie, A.; Gravitt, P. and Wu, T.C. (2008):

Molecular epidemiology of human papillomavirus. *J. Formos. Med. Assoc.*, 107: 198-217.

Hudson, A.L. (1976):

Treatment of plantar warts with bleomycin. *Arch. Dermatol.*, 112: 1179.

Hung, C.F.; Monie, A.; Alvarez, R.D. and Wu, T.C. (2007):

DNA vaccines for cervical cancer: from bench to bedside. *Exp. Mol. Med.*, 39: 679-689.

Hursthouse, M.W. (1975):

A controlled trial on the use of topical 5-fluorouracil on viral warts. *Br. J. Dermatol.*, 92: 93-96.

Hussein, M.S. (2005):

Evaluation of the efficacy of intralesional bleomycin injection in treatment of warts. Histopathologic and immunopathologic study of bleomycin injection into skin. M.Sc. Thesis, Benha University, pp. 77-90.

I

- Isçimen, A.; Aydemir, E.H.; Göksüğü, N. and Engin, B. (2004):**
Intralesional 5-fluorouracil, lidocaine and epinephrine mixture for the treatment of verrucae: a prospective placebo-controlled, single-blind randomized study. J. Eur. Acad. Dermatol. Venereol., 18: 455-458.

J

- Jacobsen, E.; McGraw, R. and McCagh, S. (1997):**
Pulsed dye laser efficacy as initial therapy for warts and against recalcitrant verrucae. Cutis, 59: 206-208.
- James, M.P.; Collier, P.M.; Aherne, W.; Hardcastle, A. and Lovegrove, S. (1993):**
Histologic, pharmacologic, and immunocytochemical effects of injection of bleomycin into viral warts. J. Am. Acad. Dermatol., 28: 933-937.
- James, W.D.; Berger, T.T. and Elston, D.M. (2006):**
Papovirus group. In: Andrews' diseases of the skin clinical dermatology, edited by Hodgson, S. and Bowler, K., 10th edition, Saunders Elsevier scientific publications, Philadelphia, pp. 403-415.
- Jenifer, F. (2000):**
Verruca plantaris past and present treatment. Connecti. Cut. Pediatric Medical Association, 9: 20-23.
- Jones, J.M.; Yu, R.; Mooney, J. and Wilson, A.(2004):**
A new and effective delivery system of bleomycin for the treatment of recalcitrant warts. J. Am. Acad. Dermatol., 9: 414.

K

Kadaja, M.; Paas, H.; Laos, T.; Ustav, E. and Ustav, M. (2009):
Mechanism of genomic instability in cells infected with the high-risk human papillomaviruses. PLoS. Pathog., 5: 1-16.

Katsambas, A. and Stefanaki, C. (2002):
Cutaneous diseases of the foot: unapproved treatments. Clin. Dermatol., 20: 689-699.

Kaufmann, R. and Landes, E. (1983):
5-Fluorouracil therapy following curettage of warts. Hautarzt., 34: 504-506.

Kirnbauer, R.; Lenz, P. and Okun, M.M. (2003):
Human papillomavirus. In: Dermatology, edited by Bologna, J.L.; Jorizzo, J.L. and Rapini, R.B., Elsevier scientific publications, Mosby, pp. 1217.

Klein, M.A. and Burns, L.J. (2008):
Ocular side effects of chemotherapy. In: Chemotherapy source book, edited by Perry, M.C., 4th edition, Williams and Wilkins scientific publications, Lippincott, pp. 175.

Koenig, R.D. and Horwitz, L.R. (1982):
Verrucae plantaris effective treatment with bleomycin: review of the literature and case presentations. J. Foot Surg., 21: 108-110.

Kohler, A.; Gottschling, M.; Förster, J.; Röwert-Huber, J.; Stockfleth, E. and Nindl, I. (2010):
Genomic characterization of a novel human papillomavirus (HPV-17) with a high viral load in a persisting wart. Virology, 399: 129-133.

Kovich, O.I. and Soldano, A.C. (2007):
Clinical pathologic correlations for diagnosis and treatment of nail disorders. Dermatol. Ther., 20: 11-16.

Krebs, H.B. (1991):

Treatment of genital condylomata with topical 5-fluorouracil. Dermatol. Clin., 9: 333-341.

Kunz, C.; Focke, F.; Saito, Y.; Schuermann, D.; Lettieri, T.; Selfridge J, et al., (2009):

Base excision by thymine DNA glycosylase mediates DNA-directed cytotoxicity of 5-fluorouracil. PLoS. Biol., 7: 967-979.

L

Läuchli, S.; Eichmann, A. and Baran, R. (2001):

Swelling of the proximal nail fold caused by underlying warts. Dermatology, 202: 328-329.

Lazo, J.S. and Chabner, B.A. (2006):

Bleomycin. In: Cancer chemotherapy and biotherapy principles and practices, edited by Chabner, B.A. and Longo, D.L., 4th edition, Williams and Wilkins scientific publications, Lippincott, pp. 345-355.

Lee, D.Y.; Park, J.H.; Lee, J.H.; Yang, J.M. and Lee, E.S. (2009):

The use of dermoscopy for the diagnosis of plantar wart. J. Eur. Acad. Dermatol. Venereol., 23: 726-727.

Lei, Y.J.; Gao, C.; An, R.; Shi, Q.; Chen, J.M.; Yuan, et al. (2008):

Development of a multiplex PCR method for detecting and typing human papillomaviruses in verrucae vulgaris. J. Virol. Methods, 147: 72-77.

Leman, J.A. and Benton, E.C. (2000):

Verrucas. Guidelines for management. Am. J. Clin. Dermatol., 1: 143-149.

Levy, S.; Furst, K. and Chern, W. (2001):

A comparison of the skin permeation of three topical 0.5% fluorouracil formulations with that of a 5% formulation. Clin. Ther., 23: 901-907.

Lewis, T.G. and Nydorf, E.D. (2006):

Intralesional bleomycin for warts: a review. *J. Drugs. Dermatol.*, 5: 499-504.

Lichon, V. and Khachemoune, A. (2007):

Plantar warts: A focus on treatment modalities. *Dermatology Nursing*, 19: 372-375.

Lipke, M.M. (2006):

An armamentarium of wart treatments. *Clin. Med. Res.*, 4: 273-293.

Longley, D.B.; Harkin, D.P. and Johnston, P.G. (2003):

Five-fluorouracil: mechanisms of action and clinical strategies. *Nat. Rev. Cancer*, 3: 330-338.

Longworth, M.S. and Laimins, L.A. (2004):

Pathogenesis of human papillomaviruses in differentiating epithelia. *Microbiol. Mol. Biol. Rev.*, 68: 362-372.

Loven, K.; Stein, L.; Furst, K. and Levy, S. (2002):

Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. *Clin. Ther.*, 24: 990-1000.

Luk, N.M.; Tang, W.Y.; Tang, N.L.; Chan, S.W.; Wong, J.K.; Hon, K.L.; et al., (2006):

Topical 5-fluorouracil has no additional benefit in treating common warts with cryotherapy: a single-centre, double-blind, randomized, placebo-controlled trial. *Clin. Exp. Dermatol.*, 31: 394-397.

Lunsford, J. M. and Swierzewsk S.J. (2000):

Plantar warts. *Health communities*, accessed 21 Jun. 2007, <<http://www.podiatrychannel.com>>.

M

Mann, R.A. and Mann, J.A. (2003):

Keratotic disorders of the plantar skin. *J. Bone Joint Surg.*, 85: 938-955.

- Meijer, B.U. and de Waard-van der Spek, F.B. (2007):**
Allergic contact dermatitis because of topical use of 5-fluorouracil (Efudix cream). *Contact Dermatitis*, 60: 57-58.
- Micali, G.; Dall'Oglio, F.; Nasca, M.R. and Tedeschi, A. (2004):**
Management of cutaneous warts: an evidence-based approach. *Am. J. Clin. Dermatol.*, 5: 311-317.
- Miller, R.A. (1984):**
Nail dystrophy following intralesional injections of bleomycin for a periungual wart. *Arch. Dermatol.*, 120: 963-964.
- Mizuno, S. and Ishida, A. (1982):**
Selective enhancement of bleomycin cytotoxicity by local anesthetics. *Biochem. Biophys. Res. Commun.*, 105: 425-431.
- Moghaddas, N. (2004):**
Periungual verrucae diagnosis and treatment. *Clin. Pediatr. Med. Surg.*, 21: 651-661.
- Moore, M.M. and Strober, B.E. (2008):**
Topical and intralesional cytotoxic agents. In: *Fitzpatrick's dermatology in general medicine*, edited by Wolff, K.; Goldsmith, L.A.; Katz, S.I.; Gilchrest, B.A.; Paller, A. and Leffoll, D.J., 7th edition, McGraw-Hill scientific publications, New York, pp. 2122-2124.
- Moore, A.Y. (2009):**
Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders. *J. Dermatol. Treat.*, 20: 328-335.
- Mosaad, I.; Younis, I. and Wahab, A.A. (1997):**
An evaluation of a new method for bleomycin intralesional injection for the treatment of recalcitrant warts. *Med. J. Cairo Univ.*, 65: 211-218.
- Motoyama, S.; Ladines, C.A.; Luis V.S.; Moruo, T. (2004):**
The role of human papillomavirus in the molecular biology of cervical carcinogenesis. *Kobe. J. Med. Sci.*, 50: 9-19.

Muir, T.; Kirsten, M.; Fourie, P. and Dippenaar, N. (2004):

Intralesional bleomycin injection for haemangiomas and congenital vascular malformations. *Pediatr. Surg. Int.*, 19: 766-773.

Munn, S.E.; Higgins, E.; Marshall, M. and Clement, M. (1996):

A new method of intralesional bleomycin therapy in the treatment of recalcitrant warts. *Br. J. Dermatol.*, 135: 969-971.

N

Nakagawa, M.; Stites, D.P.; Palefsky, J.M.; Kneass, Z. and Moscicki, A.B. (1999):

CD4-positive and CD8-positive cytotoxic T lymphocytes contribute to human papillomavirus type 16 E6 and E7 responses. *Clin. Diagn. Lab. Immunol.*, 6: 494-498.

Nakagawa, M.; Stites, D.P.; Patel, S.; Farhat, S.; Scott, M.; Hills, N.K.; et al., (2000):

Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. *J. Infect. Dis.*, 182: 595-598.

Nath, A.K. and Thappa, D.M. (2009):

Vaccines for human papillomavirus infection: a critical analysis. *Indian J. Dermatol. Venereol. Leprol.*, 75: 245-253.

Nguyen, M.M.; Nguyen, M.L.; Caruana, G.; Bernstein, A.; Lambert, P.F. and Griep, A.E. (2003):

Requirement of PDZ-containing proteins for cell cycle regulation and differentiation in the mouse lens epithelium. *Mol. Cell. Biol.*, 23: 8970-8981.

Nunley, J.R.; Wolverton, S. and Darst, M. (2008):

Systemic drugs. In: *Dermatology*, edited by Bologna, J.L.; Jorizzo, J.L. and Rapini, R.P., 2nd edition, Elsevier scientific publications, London, pp. 2011.

O

Ogunmodede, F.; Yale, S.H.; Krawisz, B.; Tyler, G.C. and Evans, A.C. (2007):
Human papillomavirus infections in primary care. Clin. Med. Res., 5: 210-217.

Olsen, R.L. (1977):
Plantar Warts yield to DNA inhibitor. JAMA., 237: 940-944.

P

Palefsky, J.M.; Gillison, M.L. and Strickler, H.D. (2006):
HPV vaccines in immunocompromised women and men. Vaccine, 24: 40-6.

Perry, M.C. and Mckinney, N.F. (2008):
Chemotherapeutic agents. In: Chemotherapy Source book, edited by Perry, M.C., 4th edition, Williams and Wilkins scientific publications, Lippincott, pp. 597.

Pienaar, C.; Graham, R.; Geldenhuys, S. and Hudson, D.A. (2006):
Intralesional bleomycin for the treatment of hemangiomas. Plast. Reconstr. Surg., 117: 221-226.

Ploylearmsaeng, S.A.; Fuhr, U. and Jetter, A. (2006):
How may anticancer chemotherapy with fluorouracil be individualized? Clin. Pharmacokinet., 45: 567-592.

Pollock, B. and Sheehan-Dare, R. (2002):
Pulsed dye laser and intralesional bleomycin for treatment of resistant hand warts. Lasers Surg. Med., 30: 135-140.

Porro, A.M.; Alchorne, M.M.; Mota, G.R.; Michalany, N.; Pignatari, A.C. and Souza, I.E. (2003):
Detection and typing of human papillomavirus in cutaneous warts of patients infected with human immunodeficiency virus type 1. Br. J. Dermatol., 149: 1192-1199.

- Pyeon, D.; Pearce, S.M.; Lank, S.M.; Ahlquist, P. and Lambert, P.F. (2009):**
Establishment of human papillomavirus infection requires cell cycle progression. PLoS. Pathog., 5: 1.

R

- Remlinger, K.A. (2003):**
Cutaneous reactions to chemotherapy drugs: the art of consultation. Arch. Dermatol., 139: 77-81.

- Reynolrs, J.F. (1996):**
Antineoplastic agents and immunosuppressants. In: Martindale: the extra pharmacopoeia, edited by Reynolrs, J.F.; Parsons, A.V. and Swetman, S.C., 31th edition, Williams and Wilkins scientific publications, London, pp. 572.

- Rivera, A. and Tyring, S.K. (2004):**
Therapy of cutaneous human Papillomavirus infections. Dermatol. Ther., 17: 441-448.

- Robertson, D.B. and Maibach, H.I. (2001):**
Dermatologic pharmacology. In: Basic and clinical pharmacology, edited by Katzung, B.G., 8th edition, Williams and Wilkins scientific publications, Middle East, pp.1060.

S

- Saif, M.W. and Chu, E. (2008):**
Antimetabolites. In: Principles and practice of oncology, edited by Devita, V.T.; Lawerence, T.S. and Rosenberg, S.A., 8th edition, Williams and Wilkins scientific publications, Lippincott, pp. 429-430.

- Saitta, P.; Krishnamurthy, K. and Brown, L.H. (2008):**
Bleomycin in dermatology: a review of intralesional applications. Dermatol. Surg., 34: 1299-1313.

Salim, A.; Leman, J.A.; McColl, J.H.; Chapman, R. and Morton, C.A. (2003):

Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease. *Br. J. Dermatol.*, 148: 539-543.

Salk, R.S.; Grogan, K.A. and Chang, T.J. (2006):

Topical 5% 5-fluorouracil cream in the treatment of plantar warts: a prospective, randomized, and controlled clinical study. *J. Drugs Dermatol.*, 5: 418-424.

Sardana, K.; Garg, V. and Relhan, V. (2010):

Complete resolution of recalcitrant periungual/subungual wart with recovery of normal nail following prick method of administration of bleomycin 1%. *Dermatol. Ther.*, 32: 407-410.

Schaeffer, A.J.; Nguyen, M.; Liem, A.; Lee, D.; Montagna, C. and Lambert, P.F. (2004):

E6 and E7 oncoproteins induce distinct patterns of chromosomal aneuploidy in skin tumors from transgenic mice. *Cancer Res.*, 64: 538-546.

Schlaak, M. and Simon, J.C. (2010):

Topical treatment of actinic keratoses with low-dose 5-fluorouracil in combination with salicylic acid- pilot study. *J. Dtsch. Dermatol. Ges.*, 8: 174-178.

Schmidt, H. and Jacobsen, F.K. (1981):

Double-blind randomized clinical study on treatment of warts with a fluorouracil-containing topical preparation. *Z. Hautkr.*, 56: 41-43.

Schroeter, C.A.; Pleunis, J. and Pannerden, C.N. (2005):

Photodynamic therapy: New treatment for resistant plantar warts. *Dermatol. Surg.*, 31: 71-75.

Schroeter, C.A.; Kaas, L.; Waterval, J.J.; Bos, P.M. and Neumann, H.A. (2007):

Successful treatment of periungual warts using photodynamic therapy: a pilot study. *J. Eur. Acad. Dermatol. Venerol.*, 21: 1170-1174.

- Scott, M.; Nakagawa, M. and Moscicki, A.B. (2001):**
Cell-mediated immune response to human papillomavirus infection. Clin. Diagn. Lab. Immunol., 8: 209-220.
- Sethi, S.; Mahajan, B.B.; Gupta, R.R. and Ohri, A. (2007):**
Comparative evaluation of the therapeutic efficacy of dermabrasion, dermabrasion combined with topical 5% 5-fluorouracil cream, and dermabrasion combined with topical placentrex gel in localized stable vitiligo. Int. J. Dermatol., 46: 875-879.
- Shelley, W.B. and Shelley, E.D. (1991):**
Intralesional bleomycin sulfate therapy for warts. A novel bifurcated needle puncture technique. Arch. Dermatol., 127: 234-236.
- Shukla, S.; Bharti, A.C.; Mahata, S.; Hussain, S.; Kumar, R.; Hedau, S.; et al., (2009):**
Infection of human papillomaviruses in cancers of different human organ sites. Indian J. Med. Res., 130: 222-233.
- Shumack, P.H. and Haddock, M.J. (1979):**
Bleomycin: an effective treatment for warts. Australas. J. Dermatol., 20: 41-42.
- Shumer, S.M. and O'Keefe, E.J. (1983):**
Bleomycin in the treatment of recalcitrant warts. J. Am. Acad. Dermatol., 9: 91-96.
- Sollitto, R.J.; Napoli, R.C.; Gazivoda, P.L. and Hart, T.J. (1989):**
A perspective study using bleomycin sulfate in the treatment of plantar verrucae. J. Foot Surg., 28: 141-144.
- Sollitto, R.J. and Pizzano, D.M. (1996):**
Bleomycin sulfate in the treatment of mosaic plantar verrucae: a follow-up study. J. Foot Ankle Surg., 35: 169-172.
- Soroko, Y.T.; Repking, M.C.; Clemment, J.A.; Mitchell, P.L. and Berg, L. (2002):**
Treatment of plantar verrucae using 2% sodium salicylate iontophoresis. Phys. Ther., 82: 1184-1191.

Soyuer, U. and Aktaş, E. (1988):

Intralesional bleomycin therapy for leishmaniasis cutis. Arch. Dermatol., 124: 1571.

Stanley, M.A. (2009):

Immune responses to human papillomaviruses. Indian J. Med. Res., 130: 266-276.

Sterling, J.C.; Handfield-Jones, S. and Hudson, P.M. (2001):

Guidelines for the management of cutaneous warts. Br. J. Dermatol., 144: 4-11.

Sterling, J.C. (2004):

Virus infections. In: Rook's textbook of dermatology, edited by Burns, T.; Breathnach, S.; Cox, N. and Griffiths, C., 7th edition, Blackwell scientific publications, Oxford, pp. 1145-1154.

Sterlinko, H.; Bergant, M. and Banks, L. (2009):

Human papillomavirus infection, cancer & therapy. Indian J. Med. Res., 130: 277-285.

Stern, Y.; Feliporich, A.; Cotton, R.T. and Segal, K. (2007):

Immunocompetency in children with recurrent respiratory papillomatosis: prospective study. Ann. Otol. Rhinol. Laryngol., 71: 116-169.

Stockfleth, E.; Nindl, I.; Sterry, W., Ulrich, C.; Schmook, T. and Meyer, T. (2004):

Human papillomaviruses in transplant-associated skin cancers. Dermatol. Surg., 30: 604-609.

Stulberg, D.L. and Hutchinson, A.G. (2003):

Molluscum contagiosum and warts. Am. Fam. Physician, 67: 1233-1240.

Susser, W.S.; Worth, D.L. and Kels, J.M. (1999):

Mucocutaneous reaction to chemotherapy. J. Am. Acad. Dermatol., 40:367-398.

Syrjänen, K.J.(2009):

Annual disease burden due to human papillomavirus 16 and 18 infections in Finland. Scand. J. Infect. Dis. Suppl., 108: 2-32.

T

Takigawa, M.; Oku, T.; Ginoza, M.; Yamada, M.; Yamamoto, T. and Kobayashi, I. (1985):

Treatment of viral warts with pressure-sensitive adhesive tape containing bleomycin sulfate. Arch. Dermatol., 121: 1108.

Thomas, M.; Pim, D. and Banks, L. (1999):

The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene., 18: 7690-7700.

Togsverd-Bo, K.; Gluud, C.; Winkel, P.; Larsen, H.K.; Lomholt, H.B.; Cramers, M, et al., (2010):

Paring and intense pulsed light versus paring alone for recalcitrant hand and foot warts: a randomized clinical trial with blinded outcome evaluation. Lasers Surg. Med., 42: 179-184.

Tosti, A. and Piraccini, B.M. (2001):

Warts of the nail unit: surgical and nonsurgical approaches. Dermatol. Surg., 27: 235-239.

U

Urman, C.O. and Gottlieb, A.B. (2008):

New viral vaccines for dermatologic disease. J. Am. Acad. Dermatol., 58: 361-370.

V

van der Velden, E.M.; Ijsselmuiden, O.E.; Drost, B.H. and Baruchin, A.M. (1997):

Dermatography with bleomycin as a new treatment for verrucae vulgaris. Int. J. Dermatol., 36: 145-150.

Vanhooteghem, O.; Richert, B. and de la Brassinne, M. (2001):
Raynaud's phenomenon after treatment of verruca vulgaris of the sole with intralesional injection of bleomycin. *Pediatr. Dermatol.*, 18: 249-251.

Viscidi, R.P.; Schiffman, M.; Hildesheim, A.; Herrero, R.; Castle, P.E.; Bratti, M.C. et al., (2004):
Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. *Cancer Epidemiol. Biomarkers Prev.*, 13: 324-327.

W

Wang, K.L. (2007):
Human papillomavirus and vaccination in cervical cancer. *J. Obstet. Gynecol.*, 46: 352-362.

Watkins, P. (2006):
Identifying and treating plantar warts. *Nurs. Stand.*, 42: 50-54.

Wendling, J.; Marchand, A.; Mauviel, A. and Verrecchia, F. (2003):
Five-fluorouracil blocks transforming growth factor-beta-induced alpha 2 type I collagen gene (COL1A2) expression in human fibroblasts via c-Jun NH2-terminal kinase/activator protein-1 activation. *Mol. Pharmacol.*, 64: 707-713.

Wright, T.C. (2009):
Natural history of HPV infections. *J. Fam. Pract.*, 58: 51-57.

Wyatt, M.D. and Wilson, D.M. (2009):
Participation of DNA repair in the response to 5-fluorouracil. *Cell Mol. Life Sci.*, 6: 788-799.

X

Xu, X.; Erickson, L.; Chen, L. and Elder, D.E. (2004):
Diseases caused by viruses. In: *Lever's histopathology of the skin*, edited by Elder, D.E.; Elenitsas, R.; Johnson, B.L.; Murphy, G.F. and Xu, X., 10th edition, Williams and Wilkins scientific publications, Lipincott, pp. 652.

Y

Yamamoto, T. (2006):

Bleomycin and the skin. Br. J. Dermatol., 155: 869-875.

Yazdanfar, A.; Farshchian, M.; Fereydoonnejad, M. and Farshchian, M. (2008):

Treatment of common warts with an intralesional mixture of 5-fluorouracil, lidocaine, and epinephrine: a prospective placebo-controlled, double-blind randomized trial. Dermatol. Surg., 34: 656-659.

Yoo, K.H.; Kim, B.J. and Kim, M.N. (2009):

Enhanced efficacy of photodynamic therapy with methyl 5-aminolevulinic acid in recalcitrant periungual warts after ablative carbon dioxide fractional laser: a pilot study. Dermatol. Surg., 35: 1927-1932.

Z

Zhang, B.; Chen, W. and Roman, A. (2006):

The E7 proteins of low- and high-risk human papillomaviruses share the ability to target the pRB family member p130 for degradation. Proc. Natl. Acad. Sci. USA., 103: 437-442.

Zhou, J.; Sun, X.Y.; Louis, K. and Frazer, I.H. (1994):

Interaction of human papillomavirus type 16 capsid protein with HPV DNA requires an intact L2 N-terminal sequence. J. Virol., 68: 619-625.

Zorn, K.K.; Gardner, G.J.; Farley, J.H. and Birrer, M.J. (2009):

The biology of gynecologic cancer. In: Principles and practice of gynecologic oncology, edited by Barakt, R.R.; Perelman, R.O.; Markman, M. and Randall, M., 5th edition, Williams and Wilkins scientific publications, Lippincott, pp. 35-39.